Highlights Modus Therapeutics Holding AB

Equities

MODTX

SE0015987904

Market Closed - Nasdaq Stockholm Other stock markets 08:40:25 2024-04-29 am EDT			5-day change	1st Jan Change
0.984 ^SEK	+1.65%		-4.00%	-43.29%

Feb. 21	Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Modus Therapeutics Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Modus Therapeutics Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-22	CI
Modus Therapeutics Announces Positive Topline Data from Phase 1b LPS Provocation Study Evaluating the Potential of Sevuparin for Treatment of Sepsis	23-02-21	CI
Modus Therapeutics Files Patent Application for Kidney Disease Drug	23-01-23	MT
Modus Therapeutics Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-22	CI
Modus Therapeutics Holding AB Completes Recruitment for Phase 1B LPS Provocation Study	22-09-27	CI
Modus Therapeutics Holding AB Announces First Patient Enrolled in the Phase I SEVUSMART Clinical Trial Evaluating Sevuparin in Paediatric Patients with Severe Malaria	22-09-01	CI
Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-23	CI
Modus Therapeutics Updates on Sevuparin Phase 1b Clinical Trial Timelines	22-05-25	CI
Modus Therapeutics Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Modus Therapeutics Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-22	CI
Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-22	CI
Modus Therapeutics publishes year-end report for 2021	22-02-22	AQ
Modus Therapeutics sums up the significant progress on key milestones during 2021, including IPO on First North Stockholm	22-01-14	AQ
Modus Therapeutics Holding AB announces first clinical trial participant dose with sevuparin clinical Phase 1b LPS provocation study	21-12-01	CI
Modus Therapeutics Holding AB Receives Approval to Initiate Clinical Phase 1B Trial with Sevuparin in the Netherlands	21-11-09	CI
Modus Therapeutics Holding AB Announces Interim Report for the Second Quarter and First Half of 2021	21-08-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Modus Therapeutics Holding AB

Equities

MODTX

SE0015987904

Highlights

Filters